Angstrom Medica Receives Recognition From Frost & Sullivan for Its Novel NanOss(TM) Technology Platform

Dec 21, 2005, 00:00 ET from Frost & Sullivan

    PALO ALTO, Calif., Dec. 21 /PRNewswire/ -- Frost & Sullivan's recent
 analysis of the advances in medical device technology for orthopedic
 applications recognized Angstrom Medica, Inc. in the field of orthopedic
 biomaterials as the recipient of the 2005 Excellence in Technology Award for
 the development of its novel nanocrystalline calcium phosphate technology --
 NanOss(TM). This technology exploits nanotechnology allowing Angstrom Medica
 to manipulate calcium and phosphate at the molecular level and create
 formulations with unique material properties including high mechanical
     Angstrom Medica, whose tagline is "the synthetic bone company", has
 incorporated NanOss chemistries in the development of both hydroxyapatite (HA)
 and tri-calcium phosphate (TCP) formulations for use as structural medical
 devices, an injectable, weight-bearing bone cement and as bioactive coatings.
     "The human bone is composed of a calcium and phosphate composite,
 specifically hydroxyapatite.  As a result, synthetic manipulations that mimic
 the natural composition, size, and morphology of bone possess better
 bioactivity," says Frost & Sullivan research analyst Nivedithaa
 Gopaalakrishnan. "Not surprisingly, NanOss finds applications where natural
 bone is damaged or removed, such as in the treatment of fractures and also as
 a replacement of allograft (donor bone) and metallic medical devices in the
 areas of spine and sports medicine."
     Angstrom Medica's nanotechnology manipulates molecules at the nanoscale
 (one millionth of a millimeter). Assembling molecules at such a scale pervades
 materials with unparalleled structural and functional properties. Furthermore,
 such molecular compounds can be tinkered to produce specific attributes.
 Angstrom Medica's patented precipitation process involves the formation of
 nanostructured calcium phosphates.
     In terms of the specific process parameters, the nanocrystalline forms are
 produced after retrieving the nanocrystals from the solvent setup. These dense
 transparent monoliths are later configured into the required shapes
 necessitated by orthopedic surgery. However, the factor that really
 differentiates NanOss chemistries over other hydroxyapatite-based ones is its
 weight bearing capacity. The minute size of NanOss crystals allows the growth
 of cells between them that gradually encompass the crystals, thereby modeling
 them into natural human bone.
     NanOss chemistries have been conceptualized and formulated to include the
 development of products under three sub-categories used as such or as carriers
 of pharmokinetic agents and orthobiologic materials. These chemistries are
 highly osetoconductive and over time, merge to become a part of the natural
 bone structure (in contrast to metal or polymer implants). The technology thus
 finds applications in the sports medicine, spine, trauma, and general
 orthopedic sectors.
     "Among present allograft techniques, NanOss solves integrity, supply and
 contamination issues as it is a synthetic bone engineered in the lab that can
 be tailored to the expected strength," notes Gopaalakrishnan. "Furthermore,
 almost any amount can be machined in NanOss as opposed to allografts that rely
 on the availability of cadaver donor bones."
     Angstrom Medica received approval by the Food and Drug Administration
 (FDA) for its NanOss material in early 2005 and further approvals are likely
 to quicken the commercialization of these nanoscale materials and devices.
 Thus, recognizing Angstrom Medica's role in advancing the use of
 nanotechnology for orthopedics Frost & Sullivan is proud to present the
 company the 2005 Award for Excellence in Technology.
     Each year Frost & Sullivan presents this Award to a company that has
 pioneered the development and introduction of an innovative technology into
 the market; a technology that has either impacted or has the potential to
 impact several market sectors. The Award lauds successful technology
 development that is expected to bring significant contributions to the
 industry in terms of adoption, change, and competitive posture. It also
 recognizes the overall technical excellence of a company and its commitment
 towards technology innovation.
     About Angstrom Medica
     Angstrom Medica is a privately-held, privately funded, biomaterials and
 medical device company engaged in the development and commercialization of its
 proprietary nanocrystalline calcium phosphate technology -- NanOss(TM).
 NanOss is an innovative structural biomaterial that utilizes nanotechnology to
 achieve nearly the strength of stainless steel while remaining highly
 osteoconductive allowing it to remodel over time into human bone.
     Earlier this year, Angstrom Medica's NanOss(TM) Bone Void Filler became
 the first ever "nanotechnology" medical device to receive FDA clearance.
 Angstrom Medica's initial product development efforts for NanOss are focused
 on applications in the sports medicine, trauma, spine and general orthopaedics
     Utilizing NanOss as a platform technology, Angstrom Medica is currently
 focused on developing:
      *  Structural NanOss -- Weight-bearing medical devices that remodel into
      *  Injectable NanOss -- Injectable, endothermic, weight bearing bone
      *  Bioactive Coatings -- Programmable bioactive coatings with
     Angstrom Medica believes that NanOss is a disruptive and enabling
 technology with inherent features and benefits that make it a favorable
 replacement for certain medical devices currently made of metals, PEEK,
 absorbable polymers, allograft, autograft and PMMA.  NanOss chemistries have
 been developed in both hydroxyapatite (HA) and tri-calcium phosphate (TCP)
      Paul J. Mraz
      Chairman and Chief Executive Officer
      (781) 933-6121 ext. 101
     About Frost & Sullivan
     Frost & Sullivan, a global growth consulting company, has been partnering
 with clients to support the development of innovative strategies for more than
 40 years. The company's industry expertise integrates growth consulting,
 growth partnership services, and corporate management training to identify and
 develop opportunities. Frost & Sullivan serves an extensive clientele that
 includes Global 1000 companies, emerging companies, and the investment
 community by providing comprehensive industry coverage that reflects a unique
 global perspective and combines ongoing analysis of markets, technologies,
 econometrics, and demographics. For more information, visit .
      Stacie Jones

SOURCE Frost & Sullivan